Literature DB >> 8824468

Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts.

M Schmoeckel1, G Nollert, M Shahmohammadi, V K Young, G Chavez, W Kasper-König, D J White, J Müller-Höcker, R M Arendt, U Wilbert-Lampen, C Hammer, B Reichart.   

Abstract

As a potential source of organs for xenotransplantation, pigs that are transgenic for human decay accelerating factor (DAF) have been bred in order to overcome hyperacute rejection. We investigated the protective effect of human DAF in a porcine working heart model perfused by human blood. Hearts of normal landrace pits served as controls. The following parameters were measured: stroke work index, coronary flow and arteriovenous oxygen consumption, 6-keto prostaglandin F1alpha and prostaglandin E2 as markers of endothelial cell activation; creatine phosphokinase and lactate dehydrogenase for evaluation of the extent of myocardial damage; TNFalpha and IL-6 as markers of mononuclear cell activation. Histological and ultrastructural investigations from myocardial tissue sections were done at the end of perfusion. Human (h) DAF appeared to inhibit complement-mediated endothelial cell activation of transgenic pig hearts successfully. This was in contrast to landrace pig hearts, which had a sixfold increase of prostaglandin levels during perfusion with human blood. The cardiac weight increase during perfusion time due to interstitial edema tended to be less in the hDAF group. Myocardial damage was minimal in transgenic hearts, whereas normal pig hearts produced a threefold increase of creatine phosphokinase and lactate dehydrogenase levels. In these hearts, electron microscopy revealed single cell necrosis of myocytes and vacuolization of mitochondria with cristae rupture. According to the results obtained in the working heart model, the breeding of pigs that are transgenic for hDAF represents a promising step to making heart xenotransplantation a clinical reality in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824468     DOI: 10.1097/00007890-199609270-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Xenotransplantation--2000.

Authors:  M J Goddard; J E Foweraker; J Wallwork
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 2.  Infectious disease issues in xenotransplantation.

Authors:  R S Boneva; T M Folks; L E Chapman
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

Review 3.  Signaling cascades in the failing heart and emerging therapeutic strategies.

Authors:  Xin He; Tailai Du; Tianxin Long; Xinxue Liao; Yugang Dong; Zhan-Peng Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

4.  Ex vivo resuscitation of adult pig hearts.

Authors:  Doreen Rosenstrauch; Hakan M Akay; Hakki Bolukoglu; Lars Behrens; Laura Bryant; Peter Herrera; Kazuhiro Eya; Egemen Tuzun; Fred J Clubb; Branislav Radovancevic; O H Frazier; Kamuran A Kadipasaoglu
Journal:  Tex Heart Inst J       Date:  2003

5.  Investigating the physiology of normothermic ex vivo heart perfusion in an isolated slaughterhouse porcine model used for device testing and training.

Authors:  Benjamin Kappler; Carlos A Ledezma; Sjoerd van Tuijl; Veronique Meijborg; Bastiaan J Boukens; Bülent Ergin; P J Tan; Marco Stijnen; Can Ince; Vanessa Díaz-Zuccarini; Bas A J M de Mol
Journal:  BMC Cardiovasc Disord       Date:  2019-11-11       Impact factor: 2.298

Review 6.  Donors for nerve transplantation in craniofacial soft tissue injuries.

Authors:  Sishuai Sun; Di Lu; Hanlin Zhong; Chao Li; Ning Yang; Bin Huang; Shilei Ni; Xingang Li
Journal:  Front Bioeng Biotechnol       Date:  2022-09-07

Review 7.  Progress Toward Cardiac Xenotransplantation.

Authors:  Richard N Pierson; Jay A Fishman; Gregory D Lewis; David A D'Alessandro; Margaret R Connolly; Lars Burdorf; Joren C Madsen; Agnes M Azimzadeh
Journal:  Circulation       Date:  2020-10-05       Impact factor: 29.690

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.